President Donald Trump is expected to announce significant findings that suggest a connection between the use of Tylenol (acetaminophen) during pregnancy, insufficient folate levels, and the development of autism in children. The announcement, anticipated from the Oval Office, will also reportedly address folinic acid as a potential therapeutic intervention for autism.
The scientific community's stance on the link between prenatal acetaminophen exposure and autism remains divided. While some observational studies have indicated a correlation, they do not establish a causal relationship. A large 2024 study involving nearly 2.5 million Swedish children found no causal link between in utero acetaminophen exposure and neurodevelopmental disorders like autism and ADHD. Conversely, a 2025 review of 46 studies suggested that higher-quality studies are more likely to show a link, while still advising cautious, time-limited use of acetaminophen during pregnancy under medical supervision. Major health organizations, including the American College of Obstetricians and Gynecologists, maintain that acetaminophen is generally considered safe for pain and fever relief during pregnancy when used appropriately, noting that untreated maternal conditions can also pose risks.
Regarding folate, its critical role in fetal development is well-established, with prenatal folic acid supplementation being a standard recommendation. Emerging research is exploring folinic acid, a derivative of folate, as a potential treatment for autism. Several studies suggest that folinic acid supplementation may lead to improvements in communication and social reciprocity in children with autism spectrum disorder (ASD). However, the efficacy and optimal use of folinic acid for autism are still subjects of ongoing investigation, requiring larger, placebo-controlled trials for confirmation.
Kenvue, the manufacturer of Tylenol, has stated that over a decade of rigorous research confirms no credible evidence linking acetaminophen to autism. The broader scientific community is closely monitoring these developments, emphasizing the principle that correlation does not equal causation and that any public health guidance should be based on comprehensive, peer-reviewed research. The focus remains on providing accurate information to empower individuals to make informed decisions in consultation with healthcare professionals.